{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:01:04Z","timestamp":1790244064779,"version":"4.1.0"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS IRG 16-184-56"],"award-info":[{"award-number":["ACS IRG 16-184-56"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024042","name":"Reproductive Scientist Development Program","doi-asserted-by":"publisher","award":["K12HD00127"],"award-info":[{"award-number":["K12HD00127"]}],"id":[{"id":"10.13039\/100024042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","award":["ECIG-2024-3-1543"],"award-info":[{"award-number":["ECIG-2024-3-1543"]}],"id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["OC200302"],"award-info":[{"award-number":["OC200302"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["OC200225"],"award-info":[{"award-number":["OC200225"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["OC240039"],"award-info":[{"award-number":["OC240039"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-19-129-01-DDC"],"award-info":[{"award-number":["RSG-19-129-01-DDC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","award":["2022-889402"],"award-info":[{"award-number":["2022-889402"]}],"id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA261987"],"award-info":[{"award-number":["R37CA261987"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>High-grade serous carcinoma (HGSC) of the ovary, fallopian tube, and peritoneum has an immunosuppressive tumor immune microenvironment (TIME), mediated in part by infiltrating innate immune cells such as macrophages, neutrophils, and myeloid-derived suppressor cells (MDSC). We hypothesize that manipulating these immunoinhibitory cells will improve both response to treatment and outcomes for patients with HGSC. Using publicly available databases, we demonstrate that higher expression of CXCR2, a chemotactic receptor for MDSCs and neutrophils, is correlated with decreased overall survival and increased infiltration of neutrophils, monocytes, and M2-like macrophages in HGSC. We targeted the migration of MDSCs and neutrophils to the TIME in the ID8-p53null mouse model of HGSC with the CXCR2-selective inhibitor SB-225002 (CXCR2i) alone or in combination with cisplatin. Tumor weight and dissemination were decreased in mice treated with single-agent cisplatin or CXCR2i. In cisplatin-treated tumors compared with vehicle-treated tumors, there was an increase in suppressive myeloid cells measured by flow cytometry and multispectral immunohistochemistry. Moreover, cisplatin-mediated modulation of tumor immune cell populations was abrogated by the addition of CXCR2i to cisplatin treatment. These findings demonstrate that inhibition of CXCR2 can slow tumor progression and decrease the proportion of immunosuppressive myeloid immune cells in the TIME. Furthermore, these data reveal new insights into detrimental chemotherapy-induced remodeling of the TIME, which should be investigated as mechanistic targets to improve outcomes in HGSC. Overall, our data demonstrate the clinical relevance and therapeutic potential of targeting CXCR2 to prevent the recruitment of tumor-promoting innate immune cells to the TIME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Chemotherapy is effective in HGSC but rarely leads to a cure. We demonstrate that chemotherapy induces active CD8+ T cells with a concomitant increase in immunosuppressive myeloid cells in the tumor microenvironment. The chemotherapy-induced migration of immunosuppressive myeloid cells is inhibited by a CXCR2i without affecting the activated T cells. We purport that inhibiting CXCR2 with chemotherapy in HGSC will improve T-cell immune surveillance in HGSC and patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0408","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:28:42Z","timestamp":1787164122000},"page":"2256-2270","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4253-2934","authenticated-orcid":false,"given":"Railey G.","family":"Mikeska","sequence":"first","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-7786","authenticated-orcid":false,"given":"Lily Elizabeth R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-7453","authenticated-orcid":false,"given":"Elizabeth R.","family":"Woodruff","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1142-4753","authenticated-orcid":false,"given":"Ritsuko","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-752X","authenticated-orcid":false,"given":"Katharine E.","family":"Linder","sequence":"additional","affiliation":[{"name":"2Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6666-5406","authenticated-orcid":false,"given":"Tomomi M.","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8126-1410","authenticated-orcid":false,"given":"Kayla","family":"Sompel","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-7157","authenticated-orcid":false,"given":"Kimberly R.","family":"Jordan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Colorado Anschutz Medical Campus 3 Department of Immunology and Microbiology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-8247","authenticated-orcid":false,"given":"Miriam D.","family":"Post","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Colorado Anschutz Medical Campus 4 Department of Pathology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4994-0636","authenticated-orcid":false,"given":"Maia","family":"Zoller","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5809-5271","authenticated-orcid":false,"given":"Benjamin G.","family":"Bitler","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-5943","authenticated-orcid":false,"given":"Nicole A.","family":"Marjon","sequence":"additional","affiliation":[{"name":"1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."},{"name":"2Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"Suppl 1","key":"2026092405043439900_bib1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"2026092405043439900_bib2","doi-asserted-by":"publisher","first-page":"15987","DOI":"10.3390\/ijms242115987","article-title":"Developments in genetics: better management of ovarian cancer patients","volume":"24","author":"Maioru","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026092405043439900_bib3","volume-title":"Survival rates for ovarian cancer","author":"American Cancer Society","year":"2025"},{"key":"2026092405043439900_bib4","doi-asserted-by":"publisher","first-page":"1328651","DOI":"10.3389\/fimmu.2023.1328651","article-title":"Targeting the immune microenvironment for ovarian cancer therapy","volume":"14","author":"Blanc-Durand","year":"2023","journal-title":"Front Immunol"},{"key":"2026092405043439900_bib5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2026092405043439900_bib6","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41416-020-1026-0","article-title":"Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer","volume":"123","author":"Yang","year":"2020","journal-title":"Br J Cancer"},{"key":"2026092405043439900_bib7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1084\/jem.20181170","article-title":"Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum","volume":"216","author":"Lee","year":"2019","journal-title":"J Exp Med"},{"key":"2026092405043439900_bib8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026092405043439900_bib9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"key":"2026092405043439900_bib10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s13671-018-0234-9","article-title":"Immunology of wound healing","volume":"7","author":"Ellis","year":"2018","journal-title":"Curr Dermatol Rep"},{"key":"2026092405043439900_bib11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis","volume":"14","author":"Xiong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026092405043439900_bib12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","article-title":"IL-8 and cancer prognosis on immunotherapy","volume":"26","author":"Bakouny","year":"2020","journal-title":"Nat Med"},{"key":"2026092405043439900_bib13","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.3390\/cancers13246293","article-title":"Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy","volume":"13","author":"Bullock","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026092405043439900_bib14","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","article-title":"Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)","volume":"22","author":"Alfaro","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026092405043439900_bib15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","article-title":"CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis","volume":"24","author":"Katoh","year":"2013","journal-title":"Cancer Cell"},{"key":"2026092405043439900_bib16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.clinbiochem.2004.01.014","article-title":"Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients","volume":"37","author":"Kassim","year":"2004","journal-title":"Clin Biochem"},{"key":"2026092405043439900_bib17","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"key":"2026092405043439900_bib18","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3389\/fimmu.2018.01977","article-title":"Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression","volume":"9","author":"Awad","year":"2018","journal-title":"Front Immunol"},{"key":"2026092405043439900_bib19","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1158\/1078-0432.CCR-22-0296","article-title":"Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026092405043439900_bib20","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res"},{"key":"2026092405043439900_bib21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.celrep.2019.12.034","article-title":"Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment","volume":"30","author":"Maniati","year":"2020","journal-title":"Cell Rep"},{"key":"2026092405043439900_bib24","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1158\/2326-6066.CIR-23-1109","article-title":"The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinoma","volume":"12","author":"Van Kleunen","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2026092405043439900_bib22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-22-0102","article-title":"ATF6-mediated signaling contributes to PARP inhibitor resistance in ovarian cancer","volume":"21","author":"McMellen","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2026092405043439900_bib23","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1158\/1078-0432.CCR-20-1762","article-title":"The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval","volume":"26","author":"Jordan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026092405043439900_bib25","doi-asserted-by":"publisher","first-page":"e9615","DOI":"10.1371\/journal.pone.0009615","article-title":"Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets","volume":"5","author":"Yoshihara","year":"2010","journal-title":"PLoS One"},{"key":"2026092405043439900_bib26","doi-asserted-by":"publisher","first-page":"100625","DOI":"10.1016\/j.xinn.2024.100625","article-title":"Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors","volume":"5","author":"Gy\u0151rffy","year":"2024","journal-title":"Innovation (Camb)"},{"key":"2026092405043439900_bib27","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026092405043439900_bib28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41419-019-1837-1","article-title":"CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18\/ERK\/STAT3","volume":"10","author":"Han","year":"2019","journal-title":"Cell Death Dis"},{"key":"2026092405043439900_bib29","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s11739-023-03309-5","article-title":"Therapeutic inhibition of CXCR1\/2: where do we stand?","volume":"18","author":"Sitaru","year":"2023","journal-title":"Intern Emerg Med"},{"key":"2026092405043439900_bib30","doi-asserted-by":"publisher","first-page":"230172","DOI":"10.1183\/16000617.0172-2023","article-title":"A narrative review of chemokine receptors CXCR1 and CXCR2 and their role in acute respiratory distress syndrome","volume":"33","author":"Toya","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026092405043439900_bib31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2026092405043439900_bib32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13148-019-0758-2","article-title":"Histone methyltransferases EHMT1 and EHMT2 (GLP\/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma","volume":"11","author":"Watson","year":"2019","journal-title":"Clin Epigenetics"},{"key":"2026092405043439900_bib33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"2026092405043439900_bib34","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/978-981-32-9755-5_7","article-title":"Analytical platforms 3: processing samples via the RPPA pipeline to generate large-scale data for clinical studies","volume-title":"Reverse phase protein arrays","author":"Siwak","year":"2019"},{"key":"2026092405043439900_bib35","doi-asserted-by":"publisher","first-page":"101389","DOI":"10.1016\/j.xpro.2022.101389","article-title":"Isolation of human and mouse myeloid-derived suppressor cells for metabolic analysis","volume":"3","author":"Choi","year":"2022","journal-title":"STAR Protoc"},{"key":"2026092405043439900_bib36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12950-022-00321-y","article-title":"The immunological function of CXCR2 in the liver during sepsis","volume":"19","author":"Liu","year":"2022","journal-title":"J Inflamm (Lond)"},{"key":"2026092405043439900_bib37","doi-asserted-by":"publisher","first-page":"eaap9520","DOI":"10.1126\/sciimmunol.aap9520","article-title":"Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells","volume":"4","author":"Gemta","year":"2019","journal-title":"Sci Immunol"},{"key":"2026092405043439900_bib38","doi-asserted-by":"publisher","first-page":"593706","DOI":"10.3389\/fonc.2020.593706","article-title":"Enolase 1 correlated with cancer progression and immune-infiltrating in multiple cancer types: a pan-cancer analysis","volume":"10","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"2026092405043439900_bib39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12964-018-0266-6","article-title":"Regulation of the master regulator FOXM1 in cancer","volume":"16","author":"Liao","year":"2018","journal-title":"Cell Commun Signal"},{"key":"2026092405043439900_bib40","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/JCI127755","article-title":"Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2)","volume":"129","author":"Markosyan","year":"2019","journal-title":"J Clin Invest"},{"key":"2026092405043439900_bib41","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2147\/OTT.S168317","article-title":"Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial-mesenchymal transition","volume":"11","author":"Chen","year":"2018","journal-title":"OncoTargets Ther"},{"key":"2026092405043439900_bib42","doi-asserted-by":"publisher","first-page":"200111","DOI":"10.1098\/rsob.200111","article-title":"Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine","volume":"10","author":"Yaseen","year":"2020","journal-title":"Open Biol"},{"key":"2026092405043439900_bib43","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.tranon.2023.101866","article-title":"Tumor associated neutrophils governs tumor progression through an IL-10\/STAT3\/PD-L1 feedback signaling loop in lung cancer","volume":"40","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"key":"2026092405043439900_bib44","first-page":"1715","article-title":"Expression of IL-10 in patients with ovarian carcinoma","volume":"26","author":"Mustea","year":"2006","journal-title":"Anticancer Res"},{"key":"2026092405043439900_bib45","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/cancers16162840","article-title":"Ascites and serum interleukin-10 levels as a prognostic tool for ovarian cancer outcomes","volume":"16","author":"Guigue","year":"2024","journal-title":"Cancers"},{"key":"2026092405043439900_bib46","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","article-title":"CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"key":"2026092405043439900_bib47","first-page":"452","article-title":"Cancer immunotherapy, part 2: efficacy, safety, and other clinical considerations","volume":"42","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"2026092405043439900_bib48","doi-asserted-by":"publisher","first-page":"577869","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"2026092405043439900_bib49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fimmu.2012.00263","article-title":"CXCR2: from bench to bedside","volume":"3","author":"Stadtmann","year":"2012","journal-title":"Front Immunol"},{"key":"2026092405043439900_bib50","doi-asserted-by":"publisher","first-page":"e1112940","DOI":"10.1080\/2162402X.2015.1112940","article-title":"Anti-\u03b1-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response","volume":"5","author":"Cappello","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026092405043439900_bib51","doi-asserted-by":"publisher","first-page":"10472","DOI":"10.1074\/jbc.M111.280321","article-title":"\u03b1-Enolase of Streptococcus pneumoniae induces formation of neutrophil extracellular traps","volume":"287","author":"Mori","year":"2012","journal-title":"J Biol Chem"},{"key":"2026092405043439900_bib52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/imm.70034","article-title":"Enolase-1 is a key regulator of neutrophil recruitment during acute inflammation","volume":"177","author":"Lu","year":"2026","journal-title":"Immunology"},{"key":"2026092405043439900_bib53","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.3390\/cancers15184456","article-title":"Granzyme B expression in the tumor microenvironment as a prognostic biomarker for patients with triple-negative breast cancer","volume":"15","author":"Mizoguchi","year":"2023","journal-title":"Cancers"},{"key":"2026092405043439900_bib54","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res"},{"key":"2026092405043439900_bib55","doi-asserted-by":"publisher","first-page":"e954471","DOI":"10.4161\/21624011.2014.954471","article-title":"Chemotherapy-induced myeloid suppressor cells and antitumor immunity: the Janus face of chemotherapy in immunomodulation","volume":"3","author":"Ding","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026092405043439900_bib56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0408\/3822523\/crc-26-0408.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2256\/3832310\/crc-26-0408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/9\/2256\/3832310\/crc-26-0408.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:04:45Z","timestamp":1790240685000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/9\/2256\/788473\/Inhibiting-CXCR2-Remodels-the-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0408","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33980931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33980922","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33980928","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33980919","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33980934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33980937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33980925","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8734860","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}